Table 1

Clinical data for glargine and SSRI groups

GlargineSSRIP
n2525
Age (years)67 ± 1063 ± 100.20
Sex (female)36440.56
BMI (kg/m2)29.1 ± 5.826.9 ± 1.70.22
Previous diabetes11 (44)14 (56)0.40
LOS (days)24.2 ± 18.223.8 ± 18.80.85
Severity-of-illness score110 ± 25105 ± 240.27
Charlson score4.9 ± 3.33.6 ± 3.40.17
Primary diagnosis
    GI cancer/mass1313
    Esophageal tear/rupture31
    Pancreatitis13
    Head and neck cancer21
    Other67
Glycemic data
    Entry glucose (mmol/l)9.8 ± 2.79.9 ± 2.7
    Study day 19.6 ± 2.39.6 ± 2.50.59
    Study day 29.7 ± 2.69.2 ± 2.30.52
    Study day 39.6 ± 2.39.2 ± 2.40.57
    Study day 49.4 ± 2.19.3 ± 2.40.98
    Study day 58.8 ± 1.89.1 ± 1.90.66
    Study day 68.6 ± 1.48.4 ± 1.60.62
    Study day 78.8 ± 1.87.8 ± 1.30.27
    Study day 87.8 ± 1.88.0 ± 1.40.48
    Mean study glucose (mmol/l)9.1 ± 1.68.9 ± 1.60.71
    Mean peak glucose (mmol/l)11.4 ± 2.711.5 ± 2.90.95
    Mean nadir glucose (mmol/l)6.9 ± 1.66.7 ± 1.20.51
Hypoglycemia
    Patient days2.74.80.34
    Blood glucose measures1.31.10.35
Insulin
    Total daily dose (units)27.2 ± 20.527.0 ± 28.50.33
    SSRI (units/day)11.3 ± 9.315.7 ± 12.40.22
    Total daily dose (units · kg−1 · day−1)0.33 ± 0.260.33 ± 0.33
    Basal insulin (%)66.9 ± 13.824.0 ± 28.70.001
    NPH and SSRI (%)*NA55.1 ± 7.00.45
Triglycerides (mmol/l)
    Baseline1.6 ± 0.51.6 ± 0.80.52
    End of study1.6 ± 0.51.6 ± 0.50.95
Adverse events (n)
    Body temperature >100.4°F (days)080.003
    Antibiotic use (days)64740.13
    Arrythmias121.0
    Pulmonary emboli210.49
    Deep venous thrombosis201.0
    Wound infection10
    Respiratory symptoms221.0
    Cardiac arrest011.0
    Liver abscess101.0
  • Data are percent, n (%), or means ± SD unless otherwise indicated.

  • *n = 12.

  • †Compared with the glargine group. GI, gastrointestinal; NA, not available.